Top Cell Therapy Companies

The global cell therapy market is driven by surging investments in R&D of stem cell and regenerative medicine. Growing prevalence of chronic diseases and use of cell therapies for the treatment of the same are also expected to boost revenue generation in the future. Technological innovations in cell manufacturing processes are also predicted to help expand the scope of application for cell therapies. Launch of new expedited regulatory pathways for cell therapy products by regulatory bodies is also slated to create new business scope for cell therapy providers. The success of CAR-T cell therapies in treating certain cancers is also projected to create a wide range of new opportunities for market players in the long run.

Industry Overview

According to SkyQuest Technology “Cell Therapy Market By Technology (Somatic Cell Technology, Cell Immortalization Technology), By Cell Type (Stem Cell, Non-stem Cell), By Therapy Type (Allogeneic Therapies, Non-Stem Cell Therapies), By Therapeutic Area, By End User, By Region - Industry Forecast 2025-2032,” Global cell therapy market is projected to grow at a CAGR of over 21.5% by 2032, as more and more indications are being treated using novel cell therapies. The shift towards personalized medicine is also expected to bolster the adoption of cell therapies as they help tailor treatments to individual patient profiles. Growing patient awareness regarding the benefits of cell therapies can also expand the demand for novel cell therapies in the future.

Top 10 Global Cell Therapy Companies

1. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is a dominant industrial partner to the cell-therapy ecosystem: it supplies the reagents, instruments, single-use bioreactors, GMP raw materials and analytics that underpin discovery, preclinical work and commercial manufacturing. The company acts as a key enabler for companies focusing on developing cell and gene therapies, biomanufacturing processes, and advanced clinical products. Thermo Fisher’s end-to-end offering for cell therapy spans frozen storage, closed-system cell processing platforms, viral vector production reagents, cell culture media, sterility and release testing systems, and cloud-connected lab informatics that support regulatory compliance. Because many smaller biotech developers outsource critical manufacturing steps, Thermo Fisher’s scale and global GMP footprint make it a first-line supplier for both early-stage and commercial cell-therapy programs; its investments in automation and integrated workflows aim to reduce per-dose cost and accelerate time to market.

2. Merck KGaA (EMD / MilliporeSigma)

Merck KGaA’s life-science arm (MilliporeSigma in the U.S.) is a foundational supplier for cell-therapy developers, offering media, buffers, viral-vector reagents, transfection systems, and process analytics. For cell therapies specifically, the company provides critical upstream and downstream materials, closed processing systems, GMP manufacturing components, and column resins used in the purification of cell products and viral vectors. The company’s investments in platform chemistry, single-use assemblies, and quality-by-design workflows are positioning it as a major player for the long run.

3. Danaher Corporation

The company’s life-science and bioprocessing businesses provide process monitoring, single-use consumables, cell-separation technologies, and automation that reduce variability in cell production. Danaher’s portfolio includes firms focused on bioprocess analytics, flow cytometry, purification, and in-line process control, is tailored to the needs of cell-therapy developers and CDMOs. Because cell therapies are highly sensitive to manufacturing conditions, Danaher’s instrumentation and software for in-process testing, environmental monitoring, and quality control are crucial for meeting regulatory release criteria and scaling production. Danaher also supports the trend toward closed, automated manufacturing suites that enable reproducible, lower-cost cell therapy manufacturing at clinical and commercial scale.

4. Becton, Dickinson and Company (BD)

BD is a leading medtech company whose devices and consumables are integral to many cell-therapy workflows. While BD’s fiscal 2024 filings cover broad medtech revenue, the company supplies critical disposables—sterile tubing sets, single-use bioprocess assemblies, syringes, infusion systems, and containment technologies—that support cell processing, formulation and delivery. Recent strategic moves (including the addition of advanced patient-monitoring and critical-care assets) expand BD’s role in the post-manufacturing care pathway for cell-therapy patients. Importantly, BD’s strength in regulatory affairs, global distribution and clinician-facing devices bridges lab manufacturing and bedside administration: clinicians rely on validated delivery systems for cell infusions, and BD’s portfolio helps customers meet traceability and safety requirements. As cell therapies advance commercially, BD’s device expertise and global reach make it a core partner for developers, CDMOs and healthcare providers.

5. Lonza Group

Lonza is one of the world’s largest CDMOs for cell and gene therapies, offering integrated process development, clinical- and commercial-scale manufacturing, viral-vector production and fill-finish services. Lonza is focusing on expanding its cell & gene capabilities and an expanding its global footprint of GMP facilities. Lonza’s value proposition is the ability to take a program from process development through scale-up to commercial production, often solving bottlenecks that small biotech companies cannot address in-house. Lonza is known for its analytical development services, supply of critical raw materials, and technology transfer to multiple manufacturing sites—services that de-risk commercialization for customers.

6. Sartorius AG

Sartorius is a specialist supplier of bioprocessing equipment and single-use technologies used extensively in cell-therapy production. Sartorius provides single-use bioreactors, filtration and chromatography modules, sensors, and automation software that enable closed, scalable cell-manufacturing processes. For cell therapies, single-use systems are attractive because they reduce contamination risk and shorten changeover times between batches, which is critical for personalized and allogeneic cell products. Sartorius’s focus on process standardization, modular manufacturing components, and process analytics helps developers shorten development timelines and support regulatory filings by providing reproducible, documented process data.

7. Nkarta Inc.

Nkarta is a clinical-stage cell-therapy company developing allogeneic (off-the-shelf) natural killer (NK) cell therapies for oncology and, in some programs, autoimmune indications. The company’s public filings and 2024/2025 results show an R&D-heavy, clinical-stage balance sheet rather than commercial product revenue. Nkarta’s platform centers on engineered NK cells designed for potency, persistence and reduced graft-versus-host risks versus traditional allogeneic T-cell products; manufacturing advances such as closed systems, standardized expansion protocols and cryopreservation are core to making NK products broadly distributable. Nkarta’s clinical readouts and IND activity (and anticipated investigator-sponsored trials) will determine its near-term value inflection points; if safety and efficacy are confirmed, scalable manufacturing and supply partnerships will be essential to convert clinical promise into commercial adoption.

8. Aurion Biotech (Aurion Biotherapeutics)

Aurion Biotech is an emerging regenerative-medicine and cell-therapy company (recently visible in funding and IPO filings) focused on ophthalmology and other localized indications. As a private / pre-commercial company it has been raising capital to support late-preclinical and early clinical work and to scale manufacturing. Aurion’s approach emphasizes development of allogeneic or engineered cell products and the manufacturing processes required for reproducible clinical supply, particularly for delicate tissues like the retina where cell delivery, dosing and immune management are specialized. The company’s fundraising and planned IPO activity indicate investor conviction in regenerative cell approaches for vision restoration, translating that into durable patient outcomes will depend on validated manufacturing workflows, regulatory approvals and distribution capabilities.

9. S. BIOMEDICS (S.Biomedics)

S.Biomedics is a European/Asian cell-therapy developer active in stem-cell programs for regenerative medicine, including fibroblast- and neuronal-precursor approaches (notably a dopamine progenitor program for Parkinson’s disease). The company is advancing multiple clinical candidates and has reported promising early-stage data for certain indications; it emphasizes platform technologies that attempt to deliver functional cell replacements and durable symptomatic improvement.

10. MEDIPOST Co. Ltd.

MEDIPOST is a South Korean pioneer in commercial cell therapy: it developed and commercialized Cartistem®, an allogeneic umbilical-cord-blood-derived stem-cell product for knee osteoarthritis, and operates a large hybrid cord-blood bank (CellTree). In 2024 the company reported roughly KRW 70.7 billion of revenue, and MEDIPOST continues to expand clinical programs and global regulatory activities (including Phase-3 IND work and trials in Japan). MEDIPOST’s model that focuses on combining biobanking, a commercial product, manufacturing capabilities and pipeline R&D demonstrates how regionally successful cell therapies can scale into exports and global trials.

Other Leading Global Cell Therapy Companies

• Novartis AG (Switzerland)
• Gilead Sciences, Inc. (US)
• Intellia Therapeutics (US)
• Anterogen Co., Ltd. (South Korea)
• JW Therapeutics (China)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Johnson & Johnson Services, Inc (US)
• Bristol-Myers Squibb Company (US)
• Iovance Therapeutics (US)
• CRISPR Therapeutics (Switzerland)

Conclusion

The global cell therapy market is anticipated to expand at a robust CAGR but faces challenges from high manufacturing costs and ethical issues. Cell therapy companies are expected to leverage artificial intelligence and other advanced digital technologies to help them fast track their R&D and manufacturing. Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms are accelerating the development and commercialization of cell therapies.